|
||
| Gilenya News Channel |  |
|
|
|||||
|
|||||
|
|||||
| MS NEWS ARCHIVES: by week | |||||
| July 2013 | |||||
| September 2013 | |||||
| October 2013 | |||||
| June 2014 | |||||
| July 2014 | |||||
| January 2015 | |||||
| February 2015 | |||||
| March 2015 | |||||
| April 2015 | |||||
| May 2015 | |||||
| July 2015 | |||||
| March 2016 | |||||
| April 2016 | |||||
| May 2016 | |||||
| June 2016 | |||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
| HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS | |||||
 |
|||||
| |||||
| |||||
 Click to view 1280 MS Walk photos! | |||||
|
|||||
|
|||||
|
|||||
Wednesday
Disease-modifying treatments for MS – a review of approved medications: STUDY
End-of-Year Task: Renewing Your DMT Prescription for 2016
By Kim Dolce—December 8, 2015
December is upon us, and besides being the holiday season, ‘tis also the season to renew our prescriptions for disease-modifying therapies and reapply for co-pay assistance.
Read more »
Labels: Aubagio, Avonex, Betaseron, Copaxone, Rebif
Pegylated Interferon Beta-1a for Multiple Sclerosis: VIDEO
The MD Magazine Peer Exchange "Modifying the Course of Multiple Sclerosis in New Ways: The Latest Advances in Treatment" features a distinguished panel of physician experts discussing key topics in multiple sclerosis (MS) research and management, including the latest insights into MS pathophysiology, new medication options and their application in clinical practice, and more.
Read more »
Labels: Aubagio, Lemtrada, Plegridy, Tecfidera, Video
FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments
This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Labels: Aubagio, Avonex, Betaseron, Copaxone, Lemtrada, Rebif, Rituxan-Rituximab, Tecfidera, Tysabri
Saturday
This Could Be Game-Changing News in the Battle Against Multiple Sclerosis
For a disease that affects more than 400,000 people in the United States and approximately 2.5 million around the globe, multiple sclerosis is arguably not getting its fair share of attention from drug developers and researchers. According to the National Institutes of Health, which has an annual budget near $40 billion, only $115 million is expected to be spent on MS research in 2015.
Read more »
Labels: Aubagio, Avonex, Daclizumab, Stem Cell, Tecfidera
Sunday
Does interferon beta therapy affect survival of multiple sclerosis patients? STUDY
Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR
Teva
soaring out in front on a single product and it is no surprise that the
Generics pack are waiting in the rear ready for the copaxone patents to
expire starting May 2014. However Biogen are backing the most winners
with a staggering $5.8 billion worth of business. #2 Avonex Biogen Idec $3.0 billion
#3 Gilenya Novartis $1.9 billion
#4 Tysabri Biogen Idec $1.7 billion
#5 Betaseron Bayer $1.1 billion
#6 Tecfidera Biogen Idec $0.9 billion
#7 Rebif EMD serono $0.6 billion
#8 Ampyra Biogen Idec $0.3 billion
#9 Aubagio Sanofi $0.2 billion
#10 Extavia Novartis $0.2 billion
Read more »
Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Avonex, Betaseron, Copaxone, Extavia, Rebif, Tecfidera, Tysabri
Data Show Declining Use of Injectables as Oral Multiple Sclerosis Therapies Gain Traction
Saturday
HOW MS MEDICATIONS DIFFER FROM EACH OTHER
Read more »
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Novantrone, Rebif, Tecfidera, Tysabri
Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral Disease-Modifying Multiple Sclerosis Therapies Ten Months Post-Launch
Tecfidera Is Off to a Quick Start
Merck KGaA shores up Rebif defenses to fend off new MS rivals
Novartis, Sanofi, Biogen tout new MS drug research
New
data is rolling out at the European Committee for Treatment and
Research in Multiple Sclerosis annual meeting this week, with the new
slate of oral treatments in the spotlight, along with a lineup of older
injectables and experimental drugs. So far, one common theme is this:
Early treatment equals better results.
Read more »Labels: Aubagio, Copaxone, Tysabri
FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments
This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Lemtrada, Rebif, Rituxan, Tecfidera, Tysabri
"COPAXONE IS HEADED OFF A CLIFF: It's painfully clear that generic competitors such as Mylan, Momenta, and Novartis' Sandoz unit will roll out generic Copaxone on time"
Oral MS drugs could exacerbate Copaxone's decline. Meanwhile,
the three main oral MS drugs -- Novartis' Gilenya, Biogen's Tecfidera,
and Sanofi's Aubagio -- could all bury Copaxone in its key U.S. market. Click to read how fast these treatments have been selling, despite their limited time on the market.
Labels: Aubagio, Copaxone, Tecfidera
Friday
Biogen Idec Inc: Tecfidera Continues Its Blistering Pace
The
company's new oral alternative to its top-selling Avonex racked up $286
million in third quarter sales, far above the $200 million forecast by
some industry analysts. Its rapid roll-out helped it capture $876
million in revenue in 2013, including $398 million in the fourth
quarter. For comparison, in the most recent quarter reported, competitor
drugs Gilenya earned $521 million and Aubagio by brought in about $60
million. read more
Labels: Aubagio, Avonex, Tecfidera
Biogen Idec Inc's high profile new multiple sclerosis drug Tecfidera won European approval
BioTrends Research Group Rolls Out The TreatmentTrends: Multiple Sclerosis 2013 Report
BioTrends Research Group, a research and advisory firms for specialized biopharmaceutical issues, finds that physician-reported patient shares for Novartis's Gilenya and Biogen Idec's Tysabri are 8 percent and 10 percent among relapsing-remitting multiple sclerosis (RR-MS) patients treated with a disease-modifying therapy (DMT) across the EU5 (France, Germany, Italy, Spain and the United Kingdom); significantly higher than those reported by EU5 neurologists surveyed in 2012.
According to a release, surveyed neurologists also report that recent changes in treatment management include a shift toward earlier and more-aggressive treatment and increased use of the anti- JCV antibody assay, changes that are consistent with the increased patient shares reported for Gilenya and Tysabri. Survey data indicate that these agents occupy distinct niches, with Gilenya a preferred second-line therapy in JCV-positive patients and Tysabri a preferred second-line therapy in JCV-negative patients.
The TreatmentTrends: Multiple Sclerosis (EU) 2013 report finds that, despite fewer than 30 percent of surveyed neurologists reporting access to Genzyme's* Aubagio and Genzyme/Bayer HealthCare's Lemtrada--and given the limited time these agents had been available at the time the survey was fielded--these DMTs have nevertheless captured a 1 percent physician-reported weighted MS patient share. The data also reveal that surveyed neurologists anticipate substantial changes in DMT use in the coming months as access to Aubagio and Lemtrada expands and as new products, notably Biogen Idec's Tecfidera, become available. Neurologists indicate that Aubagio will most likely compete with first-line products (i.e., Biogen Idec's Avonex, Bayer HealthCare's Betaferon and Teva's Copaxone), while Tecfidera may replace these products as well as Merck Serono's Rebif and Gilenya. Lemtrada, conversely, will most likely compete with Tysabri or would not replace an existing DMT, suggesting anticipated use as a last-line therapy.
"The European MS market is entering a dynamic period with two recent DMT launches and as many as six new DMTs launching in the next five years," said Decision Resources Group Senior Business Insights Analyst Georgiana L. Kuhlmann, S.M. "Our data find that gains for new brands will likely come at the expense of the interferon-beta therapies and Copaxone."
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.
Decision Resources Group is a cohesive portfolio of companies that offers information and insights on sectors of the healthcare industry.
Read more »
Labels: Aubagio, Avonex, Betaseron, Copaxone, Lemtrada, Rebif, Tecfidera, Tysabri
Daniel Kantor, MD, on Specialty Pharmacy in Multiple Sclerosis
In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
“In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
“In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
See Video Here
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Novantrone, Rebif, Tecfidera, Tysabri
Surveyed Neurologists Report Significantly Higher Relapsing-Remitting Multiple Sclerosis Patient Shares for Gilenya and Tysabri, Compared With One Year Ago
The TreatmentTrends: Multiple Sclerosis (EU) 2013 report finds that, despite fewer than 30 percent of surveyed neurologists reporting access to Genzyme's* Aubagio and Genzyme/Bayer HealthCare's Lemtrada—and given the limited time these agents had been available at the time the survey was fielded—these DMTs have nevertheless captured a 1 percent physician-reported weighted MS patient share. The data also reveal that surveyed neurologists anticipate substantial changes in DMT use in the coming months as access to Aubagio and Lemtrada expands and as new products, notably Biogen Idec's Tecfidera, become available. Neurologists indicate that Aubagio will most likely compete with first-line products (i.e., Biogen Idec's Avonex, Bayer HealthCare's Betaferon and Teva's Copaxone), while Tecfidera may replace these products as well as Merck Serono's Rebif and Gilenya. Lemtrada, conversely, will most likely compete with Tysabri or would not replace an existing DMT, suggesting anticipated use as a last-line therapy.
"The
European MS market is entering a dynamic period with two recent DMT
launches and as many as six new DMTs launching in the next five years,"
said Decision Resources Group Senior Business Insights Analyst Georgiana L. Kuhlmann, S.M. "Our data find that gains for new brands will likely come at the expense of the interferon-beta therapies and Copaxone."
Click here to read more
Click here to read more
Labels: Aubagio, Avonex, Copaxone, Lemtrada, Rebif, Tecfidera, Tysabri